Tropisetron



Tropisetron
Systematic (IUPAC) name
[(1S,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl] 1H-indole-3-carboxylate
Identifiers
CAS number 89565-68-4
ATC code A04AA03
PubChem 72165
Chemical data
O2 
Mol. mass 284.353 g/mol
SMILES search in eMolecules, PubChem
Pharmacokinetic data
Bioavailability ~60–80%
Protein binding 71%
CYP2D6)
Half life 6–8 hours
Excretion Renal, Fecal
Therapeutic considerations
Pregnancy cat.

X(AU)

Legal status

Prescription Only (S4)(AU) POM(UK)

Routes Oral, IM

Tropisetron (Novartis in Europe, Australia and New Zealand as Navoban, but is not available in the U.S.

Adverse effects

Tropisetron is a well-tolerated drug with few side effects. Headache, constipation, and dizziness are the most commonly reported side effects associated with its use. There have been no significant drug interactions reported with this drug's use. It is broken down by the hepatic cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system.

References

  1. ^ Muller, W.; T. Stratz (2004). "Local treatment of tendinopathies and myofascial pain syndromes with the 5-HT3 receptor antagonist tropisetron". Scand J Rheumatic Suppl. 119: 44–48. PMID 15515413. Retrieved on 2007-05-17.
v • d • e
Aprepitant)
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Tropisetron". A list of authors is available in Wikipedia.